Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 6/20 | 0.40 |
| ▸ | CA2 | P00918 | 6/20 | 0.40 |
| ▸ | PIN1 | Q13526 | 3/20 | 0.40 |
| ▸ | GRN | P28799 | 1/20 | 0.37 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.37 |
| ▸ | UBASH3B | Q8TF42 | 1/20 | 0.35 |
| ▸ | TOP2A | P11388 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL773371 | 0.80 | CA2 (0.39) | CA1CA2PIN1GRNSORT1 | |
| SCHEMBL3217924 | 0.75 | PIN1 (0.50) | CA1CA2PIN1GRNSORT1 | |
| SCHEMBL775406 | 0.75 | GRN (0.56) | CA1CA2PIN1GRNSORT1 | |
| SCHEMBL3197482 | 0.75 | GRN (0.56) | CA1CA2PIN1GRNSORT1 | |
| SCHEMBL775888 | 0.74 | PIN1 (0.43) | CA1CA2PIN1GRNSORT1 | |
| SCHEMBL3215269 | 0.74 | PDK1 (0.52) | CA1CA2PIN1GRNSORT1 | |
| SCHEMBL14668918 | 0.73 | ERAP2 (0.39) | CA1CA2PIN1 | |
| SCHEMBL14667374 | 0.71 | LNPEP (0.40) | — | |
| SCHEMBL3217168 | 0.69 | PDK1 (0.50) | CA1CA2PIN1GRNSORT1 | |
| SCHEMBL20011787 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120071513-A1 | Compositions and Their Use as Anti-Tumor Agents | COMPASS PHARMACEUTICALS LLC (US) | 2012-03-22 | — | — | US | claimed |
| US-20110178087-A1 | Compositions and Their Use as Anti-Tumor Agents | Compass Pharmaceuticals LLC. (US) | 2011-07-21 | — | — | US | claimed |
| US-20090018145-A1 | Compositions and their use as anti-tumor agents | COMPASS PHARMACEUTICALS LLC (US) | 2009-01-15 | — | — | US | claimed |
| US-20120071513-A1 | Compositions and Their Use as Anti-Tumor Agents | COMPASS PHARMACEUTICALS LLC (US) | 2012-03-22 | — | — | US | disclosed |
| US-20110178087-A1 | Compositions and Their Use as Anti-Tumor Agents | Compass Pharmaceuticals LLC. (US) | 2011-07-21 | — | — | US | disclosed |
| US-20090018145-A1 | Compositions and their use as anti-tumor agents | COMPASS PHARMACEUTICALS LLC (US) | 2009-01-15 | — | — | US | disclosed |
| EP-1802606-A2 | COMPOSITIONS AND THEIR USE AS ANTI-TUMOR AGENTS | Compass Pharmaceuticals LLC (US) | 2007-07-04 | — | — | EP | disclosed |
| WO-2006044975-A2 | COMPOSITIONS AND THEIR USE AS ANTI-TUMOR AGENTS | COMPASS PHARMACEUTICALS LLC (US) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071513-A1 | Compositions and Their Use as Anti-Tumor Agents | TP53, VHL, RB1 | CA1 216/4885CA2 901/4885PIN1 4406/4885 |
| US-20110178087-A1 | Compositions and Their Use as Anti-Tumor Agents | TP53, VHL, RB1 | CA1 216/4885CA2 901/4885PIN1 4406/4885 |
| US-20090018145-A1 | Compositions and their use as anti-tumor agents | TP53, VHL, RB1 | CA1 153/4885CA2 768/4885PIN1 4562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.